KALETRA 400 MG / 5 ML
LOPINAVIR : 400 MG / 5 ML RITONAVIR : 100 MG / 5 ML · DIN 02243644 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is KALETRA?
KALETRA 400 MG / 5 ML contains LOPINAVIR : 400 MG / 5 ML RITONAVIR : 100 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02243644, held by ABBVIE CORPORATION, supplied as SOLUTION for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Jun-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is KALETRA used for?
KALETRA (lopinavir/ritonavir) is indicated in combination with other antiretroviral agents when therapy is warranted for the treatment of HIV-1 infection. The use of other active agents with KALETRA is associated with a greater likelihood of treatment response. Genotypic or phenotypic testing and/or treatment history should guide the use of KALETRA.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02243644 |
|---|---|
| Brand name | KALETRA |
| Generic / active ingredient | LOPINAVIR : 400 MG / 5 ML RITONAVIR : 100 MG / 5 ML |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 400 MG / 5 ML |
| Dosage form | SOLUTION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AR10 LOPINAVIR AND RITONAVIR |
| AHFS class | 08:18.08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Jun-2014 |
| Original market date | 2001-03-09 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code J05AR10 LOPINAVIR AND RITONAVIR. 3 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| KALETRA | 25 MG | TABLET | ABBVIE CORPORATION | MARKETED | DIN 02312301 |
| KALETRA | 50 MG | TABLET | ABBVIE CORPORATION | MARKETED | DIN 02285533 |
| KALETRA | 133.3 MG | CAPSULE | ABBVIE CORPORATION | CANCELLED POST MARKET | DIN 02243643 |
Who else supplies LOPINAVIR AND RITONAVIR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LOPINAVIR AND RITONAVIR appears in 8 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.